DelMar Pharmaceuticals to Present Additional Data on VAL-083 as a Potential Treatment for Temozolomide-Resistant GBM at AACR Advances in Brain Cancer Research Conference May 7, 2015 • 8:05 AM EDT
DelMar Pharmaceuticals to Present Data Supporting the Development of VAL-083 in Refractory Glioblastoma Multiforme and Non-Small Cell Lung Cancer at the American Society of Clinical Oncology (ASCO) Annual Meeting April 30, 2015 • 7:05 AM EDT
DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) April 20, 2015 • 1:00 PM EDT
DelMar Pharmaceuticals Presents Updated Clinical Data on Phase I/II Study of VAL-083 in Refractory Glioblastoma Multiforme (GBM) April 20, 2015 • 8:00 AM EDT
DelMar Pharmaceuticals Presents Positive Preclinical Data on VAL-083 for Treatment of Non-Small Cell Lung Cancer at the American Association of Cancer Research Annual Meeting April 19, 2015 • 1:00 PM EDT
DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma April 16, 2015 • 8:05 AM EDT
DelMar Pharmaceuticals Announces Panel Participation in Cancer Advance Boston Conference on April 14, 2015 April 7, 2015 • 8:00 AM EDT
DelMar Pharmaceuticals Appoints Biopharmaceutical Industry Veteran, Erich Mohr, Ph.D., R.Psych., to the Board of Directors April 1, 2015 • 8:05 AM EDT
DelMar Pharmaceuticals to Present at the 27th Annual ROTH Conference on March 10, 2015 March 3, 2015 • 8:00 AM EST
DelMar Pharmaceuticals Receives Notice of Allowance of Fourth U.S. Patent Covering Methods of Use and Compositions for VAL-083 March 2, 2015 • 11:17 AM EST